Leena Gandhi, a thoracic oncologist, started working with cancer immunotherapies in 2008 in one of the first trials of the PD1 inhibitor nivolumab and has been hooked on the field ever since. In the subsequent decade, she coordinated dozens of immuno-oncology trials — first at Dana Farber Cancer Institute, then at New York University’s Perlmutter Cancer Center — including a seminal study defining the use of PDL1 as a biomarker for PD1 inhibition in lung cancer. After a 2-year stint overseeing immuno-oncology at Eli Lilly, Gandhi is now returning to the Dana Farber Cancer Institute as Director of its new Center for Therapeutic Innovation. She spoke with Asher Mullard about the appeal of immunotherapies, how they have impacted academic drug development, and the hunt for better biomarkers that can unravel their complicated biological effects.

中文翻译：

---

蕾娜·甘地（Leena Gandhi）。

胸部肿瘤学家Leena Gandhi于2008年在PD1抑制剂nivolumab的首批试验之一中开始从事癌症免疫疗法的研究，此后便开始涉足这一领域。在随后的十年中，她协调了数十项免疫肿瘤试验-首先是在达纳·法伯癌症研究所，然后是在纽约大学的Perlmutter癌症中心-包括一项开创性研究，该研究定义了将PDL1用作抑制PD1抑制肺癌的生物标志物。在Eli Lilly监督免疫肿瘤学2年后，Gandhi现在返回达纳法伯癌症研究所，担任其新的治疗创新中心主任。她与Asher Mullard谈了关于免疫疗法的吸引力，它们如何影响学术药物开发以及寻找更好的生物标记物以揭示其复杂的生物学作用的话题。